Atherosclerosis plus最新文献

{"title":"“Fear of missing out”: Does upfront combination therapy following acute coronary syndrome (ACS) significantly decrease subsequent eligibility for injectable lipid-lowering therapies?","authors":"J. Fenwick , H. Sinclair , S.A. Tee","doi":"10.1016/j.athplu.2025.10.009","DOIUrl":"10.1016/j.athplu.2025.10.009","url":null,"abstract":"","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Page 5"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145808469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innate immune cell function in statin-treated patients with severe hypercholesterolemia is comparable to normocholesterolemic individuals: A cross-sectional study","authors":"Harsh Bahrar ,&nbsp;Kim Steward ,&nbsp;Liesbeth van Emst ,&nbsp;Nils Rother ,&nbsp;Jeanine E. Roeters van Lennep ,&nbsp;Mihai G. Netea ,&nbsp;Siroon Bekkering ,&nbsp;Niels P. Riksen","doi":"10.1016/j.athplu.2025.11.004","DOIUrl":"10.1016/j.athplu.2025.11.004","url":null,"abstract":"<div><h3>Background and aims</h3><div>Hypercholesterolemia is a major risk factor for atherosclerotic cardiovascular disease. Innate immune cells, including monocytes and neutrophils, play important roles in the pathophysiology of atherosclerosis. We previously reported that monocytes from patients with severely elevated low-density lipoprotein (LDL) cholesterol (LDL-c &gt; 4.9 mmol/l) have a hyperresponsive phenotype, which persists even after three months statin treatment. This long-term hyperresponsive innate immune phenotype is termed trained immunity (innate immune memory), and is mediated by persistent enrichment of activating histone modifications leading to higher chromatin accessibility. In this study we investigated the monocyte and neutrophil phenotype of patients with severe hypercholesterolemia treated for 12 months with statins, compared to normocholesterolemic controls.</div></div><div><h3>Methods</h3><div>In a multicentric cross-sectional study, treatment-naïve patients with severe hypercholesterolemia (defined as LDL-cholesterol &gt;4.9 mmol/L) requiring statin treatment were included. Blood was drawn after 12 months of lipid lowering therapy with statins (n = 15) and compared to healthy normocholesterolemic controls (LDL-c&lt;3.5 mmol/l; n = 18).</div><div>We assessed monocyte phenotype with flow cytometry, cytokine production capacity of PBMCs, and H3K4me3 expression on the <em>TNFA</em> promotor. In addition, we assessed the neutrophil phenotype and function.</div></div><div><h3>Results</h3><div>Treatment lowered LDL-c from 5.8 to 2.7 mmol/L. PBMC cytokine production capacity, as well as the expression of H3K4me3 histone mark on the <em>TNFA</em> promotor did not differ from the controls (LDL-c 2.6 mmol/L). Although neutrophil CD11b, CD66b, and CD62L expression was the same, production of several granular proteins was lower in patients.</div></div><div><h3>Conclusions</h3><div>Previous studies reported hyperresponsive monocytes in treatment-naïve patients with LDL-c &gt; 4.9 mmol/l. We now demonstrate that in an independent cohort of patients with LDL-c &gt; 4.9 who are treated for 12 months with lipid-lowering drugs, the monocyte phenotype and function was similar to that of normocholesterolemic controls. In addition, neutrophils phenotype was similar, while the secretion of several granular proteins was lower in the patients.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"62 ","pages":"Pages 53-61"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145748238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging cytokines contribute to the clinical manifestation of carotid artery plaque formation and stability in patients with diabetes","authors":"Zhongqing Xu ,&nbsp;James Healy ,&nbsp;Wenhui Dong ,&nbsp;JingJing Ding ,&nbsp;Xiaoyi Shen ,&nbsp;Xianzhen Feng ,&nbsp;Jun Zhou ,&nbsp;Rajesh Puranik ,&nbsp;Brett D. Hambly ,&nbsp;Shisan Bao","doi":"10.1016/j.athplu.2025.07.003","DOIUrl":"10.1016/j.athplu.2025.07.003","url":null,"abstract":"<div><h3>Background</h3><div>Type 2 diabetes mellitus (T2DM) promotes atherosclerosis and plaque instability through chronic inflammation and immune dysregulation. Emerging evidence implicates members of the interleukin-1 family—particularly IL-36, IL-37, and IL-38—in the modulation of inflammatory responses in diabetic and non-diabetic vascular disease. However, their roles in carotid atherosclerosis remain poorly defined.</div></div><div><h3>Methods</h3><div>In this retrospective observational study, circulating cytokine levels were assessed in 20 T2DM and 40 non-DM individuals using ELISA. Carotid plaque samples (n = 50) were collected from endarterectomy procedures and categorised as stable (asymptomatic, n = 25) or unstable (symptomatic, n = 25) according to AHA criteria. Immunohistochemistry quantified local expression of IL-36α, IL-36β, IL-36γ, IL-37, and IL-38.</div></div><div><h3>Results</h3><div>Circulating IL-36α, IL-36β and IL-36γ were significantly elevated in T2DM patients, while IL-37 and IL-38 levels were unchanged. Immunohistochemistry revealed significantly increased expression of all five cytokines in unstable versus stable plaques. Stratification by diabetic status showed that this upregulation was exclusive to diabetic patients. Notably, IL-36β exhibited the most pronounced increase—over 25-fold—in unstable diabetic plaques. IL-37 and IL-38 were also elevated locally, likely reflecting compensatory anti-inflammatory responses, though their circulating levels remained unaffected.</div></div><div><h3>Conclusions</h3><div>This study demonstrates differential expression of IL-36, IL-37, and IL-38 in carotid atherosclerotic plaques, with IL-36β emerging as a key pro-atherogenic cytokine in the diabetic setting. The distinct expression patterns of these cytokines in diabetic versus non-diabetic plaques suggest that T2DM exacerbates immune imbalance in atherosclerosis. These findings may inform future research on cytokine-targeted therapies for diabetic vascular complications.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 41-47"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144780425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between dolutegravir based first-line antiretroviral regimens and dyslipidemia among adults living with HIV on follow-up at health facilities in Hawassa city administration, Sidama region: a cross-sectional study","authors":"Agete Tadewos Hirigo ,&nbsp;Alemayehu Abera ,&nbsp;Daniel Yilma ,&nbsp;Ayalew Astatkie ,&nbsp;Zelalem Debebe","doi":"10.1016/j.athplu.2025.08.001","DOIUrl":"10.1016/j.athplu.2025.08.001","url":null,"abstract":"<div><h3>Background</h3><div>Inconsistent evidence on lipid alterations in people living with HIV (PLWH) on dolutegravir (DTG)-based antiretroviral therapy (ART) highlights the need for further study. This study aimed to assess the association between DTG-based regimens and dyslipidemia among adults initiated on ART after the test-and-treat implementation in Ethiopia.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted in Hawassa City Administration, Sidama region, southern Ethiopia from January 2023 to May 2024. Participants were selected using systematic random sampling. Sociodemographic, clinical, and other relevant data were collected using a semi-structured questionnaire, supplemented by a review of medical records. Dyslipidaemia was classified based on the NCEP ATP III guidelines. A binary logistic regression model was fitted to identify factors associated with dyslipidemia. An adjusted odds ratio (aORs) and 95 % confidence intervals (CIs) were computed to determine the strength of the association, with statistical significance set at p &lt; 0.05.</div></div><div><h3>Results</h3><div>Of the 465 eligible adults, 450 participated in the study, attaining a response rate of 96.8 %. Of these, 262 (58.2 %) were female. Overall, 74.0 % (95 % CI: 69.8 %–78.0 %) of participants had dyslipidemia, with a higher prevalence in males (79.8 %) than in females (69.8 %). Low HDL-cholesterol was the most common lipid abnormality (66.4%), followed by high triglyceride and elevated total cholesterol/HDL-cholesterol ratio (each 34.2 %). ART initiation with DTG-based first-line regimen (aOR: 4.8; 95 %CI: 1.2–18.5), increased waist circumference (aOR: 1.06; 95 %CI: 1.01–1.11) and neck circumference (aOR: 1.2; 95 %CI: 1.06–1.5) were significantly associated with dyslipidemia.</div></div><div><h3>Conclusion</h3><div>Based on the study findings, we recommend that routine lipid monitoring be integrated into the clinical management of PLWH on ART, to enable early detection and timely intervention for dyslipidemia.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 48-57"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144828726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proposed lipidology and preventive cardiology research priorities in Africa; Results of a Delphi survey","authors":"Alexander R.M. Lyons ,&nbsp;Frederick J. Raal ,&nbsp;Brett S. Mansfield ,&nbsp;David Marais ,&nbsp;Neusa P.J. Jessen ,&nbsp;Lambert T. Appiah ,&nbsp;Lilian Mbau ,&nbsp;Bernard Samia ,&nbsp;Ashraf Reda ,&nbsp;Tigist S. Mekonnen ,&nbsp;Albertino Damasceno ,&nbsp;Chala F. Oljira ,&nbsp;Meral Kayikcioglu ,&nbsp;Alberto Zambon","doi":"10.1016/j.athplu.2025.05.003","DOIUrl":"10.1016/j.athplu.2025.05.003","url":null,"abstract":"<div><div>Despite a population of over 1.5 billion, lipidology and preventive cardiology research of African origin is lacking in quantity and impact, and accounts for a small percentage of outputs globally due to limited resources to address the full breadth of unexplored research areas. We therefore conducted a Delphi survey on an expert panel of African clinical investigators to ascertain the proposed areas of priority to provide guidance on the future direction of African research in this field. Round one of the survey generated 58 proposed unanswered questions, and subsequent priority ratings of 1–5 of the proposed questions in two further rounds resulted in 42 priority research questions (PRQs) based on a two-thirds majority rating of 3–5 with 5 being the highest rating. Common themes amongst the 42 PRQs included mostly prevalence and distribution studies on hyperlipidaemia and lipid profiles and their risk of cardiovascular disease with emphasis on atherosclerotic cardiovascular disease, aortic stenosis, coronary artery disease, and acute coronary syndrome. The need for a cardiovascular risk score calculator appropriate for the different, diverse African populations was also emphasised. In conclusion, the results of this Delphi survey highlight a number of unanswered PRQs in lipidology and preventive cardiology in Africa that may be helpful to inform the strategic direction of future studies, education and funding in that underrepresented part of the world based on current priorities and may also have relevance globally.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 18-22"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipidome of high-density lipoprotein is strongly perturbed in hyperalphalipoproteinemia resulting from a rare mutation in endothelial lipase","authors":"Livia Pisciotta ,&nbsp;Marie Lhomme ,&nbsp;Chiara Pavanello ,&nbsp;Maharajah Ponnaiah ,&nbsp;Arianna Strazzella ,&nbsp;Alice Ossoli ,&nbsp;Wilfried Le Goff ,&nbsp;Laura Calabresi ,&nbsp;Anatol Kontush","doi":"10.1016/j.athplu.2025.07.001","DOIUrl":"10.1016/j.athplu.2025.07.001","url":null,"abstract":"<div><div>Both low and extremely high concentrations of high-density lipoprotein (HDL)-cholesterol are associated with elevated cardiovascular risk. As extremely high HDL-cholesterol states of hyperalphalipoproteinemia (HALP) are rare, HDL particles in this condition remain poorly characterised. HALP may result from mutations in endothelial lipase (EL), a hydrolytic enzyme present in the circulation. Using targeted LC/MS-MS, we quantified the lipidome of HDL isolated from three female subjects with HALP caused by a heterozygous [c.526 G &gt; T, p.(Gly176Trp)] variant of the <em>LIPG</em> gene and compared them with two healthy female controls. Our findings revealed a strongly perturbed HDL lipidome primarily involving enrichment in several phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine plasmalogen, and lysophosphatidylethanolamine species. Some of these differences were equally observed in whole plasma. These alterations may reflect perturbations of lipoprotein metabolism secondary to defective lipid hydrolysis by EL and may have consequences for atheroprotective HDL functions.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 35-40"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144657222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of lipid-lowering medications on oxidized phospholipids in individuals with elevated LIPOPROTEIN(a)","authors":"Amalia Despoina Koutsogianni ,&nbsp;Fotios Barkas ,&nbsp;Constantinos Tellis ,&nbsp;Alexandros Tselepis ,&nbsp;George Liamis ,&nbsp;Sotirios Tsimikas ,&nbsp;Evangelos Liberopoulos","doi":"10.1016/j.athplu.2025.09.003","DOIUrl":"10.1016/j.athplu.2025.09.003","url":null,"abstract":"<div><h3>Background/introduction</h3><div>Oxidized phospholipids (OxPLs) are bound to apolipoprotein B-100 (OxPL-apoB) and apolipoprotein(a) [OxPL-apo(a)] and are present freely within the phospholipid shell of apoB-containing lipoproteins. OxPLs have been linked with the pro-inflammatory properties of lipoprotein(a) [Lp(a)]. OxPLs carried on plasminogen (OxPL-PLG) may extend the time to fibrinolysis.</div></div><div><h3>Purpose</h3><div>To evaluate the effect of lipid-lowering medications on OxPLs levels in individuals with elevated Lp(a) concentrations.</div></div><div><h3>Methods</h3><div>In this prospective study, patients (n = 70) with Lp(a) levels ≥75 nmol/L were assigned to 3 treatment regimens according to current guidelines: high-intensity statin monotherapy (n = 28), ezetimibe added to high-intensity statin (n = 31) and proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) added to high-intensity statin plus ezetimibe (n = 11). Follow-up duration was 3 months.</div></div><div><h3>Results</h3><div>Patients had a mean age of 51 ± 15 years, 40 % were male, 39 % were diagnosed with familial hypercholesterolemia, 16 % had atherosclerotic cardiovascular disease, and 36 %, 33 % and 15 % were at very high, high, and moderate cardiovascular risk, respectively. Lp(a) levels did not change significantly with high-intensity statin and add-on ezetimibe but significantly decreased with add-on PCSK9i treatment. OxPL-apoB and OxPL-apo(a) significantly increased, while OxPL-PLG significantly decreased with both high-intensity statin and add-on ezetimibe. Add-on PCSK9i treatment was associated with no significant changes in OxPL-apoB, OxPL-apo(a) and OxPL-PLG levels.</div></div><div><h3>Conclusions</h3><div>Among patients with elevated Lp(a), both high-intensity statin and add-on ezetimibe significantly increased OxPL-apoB and OxPL-apo(a) levels, while significantly decreased OxPL-PLG levels. Add-on PCSK9i had no significant effect on OxPLs levels. The clinical implications of these findings should be further explored.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 58-66"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative 10-year atherosclerotic cardiovascular disease risk in Ethiopian HIV patients on first-line versus second-line combined antiretroviral therapy","authors":"Balew Arega ,&nbsp;Gashaw Solela ,&nbsp;Tariku Fekadu ,&nbsp;Tirhas Tadesse ,&nbsp;Bekele Alemayehu ,&nbsp;Amanuel Zeleke ,&nbsp;Kidat Ayele","doi":"10.1016/j.athplu.2025.06.002","DOIUrl":"10.1016/j.athplu.2025.06.002","url":null,"abstract":"<div><h3>Background</h3><div>Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality in HIV patients, but the impact of combined antiretroviral therapy regimens on its risk in Ethiopia is unclear. This study assessed the 10-year ASCVD risk in first-line versus second-line combined antiretroviral therapy and identified predictors of intermediate-to-high risk.</div></div><div><h3>Methods</h3><div>A comparative cross-sectional study was conducted among HIV patients on first-line and second-line combined antiretroviral therapy, randomly selected from government hospitals in Addis Ababa. A total of 340 patients were initially selected, with 331 included in the final analysis. Data were extracted from combined antiretroviral therapy registers and medical records. The 10-year atherosclerotic cardiovascular disease risk was estimated via pooled cohort risk equations. Logistic regression identified predictors of intermediate-to-high 10-year atherosclerotic cardiovascular disease risk (≥7.5 %).</div></div><div><h3>Results</h3><div>The mean age was 53.2 ± 9.1 years, and 55.9 % were male. Among the total patients, 223 (67.5 %) were on first-line combined antiretroviral therapy, and 108 (32.5 %) were on second-lin<strong>e</strong> therapy<strong>.</strong> The proportion of participants with an intermediate-to-high 10-year ASCVD risk was 28.7 % (95 % CI: 25.7–33.8 %), with a significantly higher prevalence observed in the second-line combined antiretroviral therapy group (36.1 %) compared to the first-line group (25.1 %) (p = 0.005). Second-line combined antiretroviral therapy (AOR = 2.3; 95 % CI: 1.23–3.22; p = 0.02), detectable viral load (AOR = 1.73; 95 % CI: 1.04–2.88; p = 0.04), alcohol use (AOR = 2.01; 95 % CI: 1.23–3.49; p = 0.01), and being divorced (AOR = 4.10; 95 % CI: 3.14–9.66; p = 0.001) or widowed (AOR = 6.64; 95 % CI: 3.69–11.59; p = 0.02) were significantly associated with intermediate-to-high 10-year ASCVD risk.</div></div><div><h3>Conclusion</h3><div>Second-line antiretroviral therapy and modifiable risk factors were associated with significantly higher 10-year ASCVD risk. Routine screening and lipid management should be integrated into HIV care, particularly for patients on second-line therapy.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 23-28"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk","authors":"Antonio Centola ,&nbsp;Michelangelo Carbonara ,&nbsp;Serena De Nuzzo ,&nbsp;Andrea Cuculo ,&nbsp;Antonio Ruggiero ,&nbsp;Giulio Campanale ,&nbsp;Massimo Iacoviello ,&nbsp;Paola Gargiulo ,&nbsp;Pasquale Perrone Filardi ,&nbsp;Natale Daniele Brunetti","doi":"10.1016/j.athplu.2025.09.001","DOIUrl":"10.1016/j.athplu.2025.09.001","url":null,"abstract":"<div><h3>Background</h3><div>A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9. Less is known on real world and every-day practice patients.</div></div><div><h3>Methods</h3><div>Fifty consecutive patients with or at risk of atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) and treated with inclisiran according to Italian indications were enrolled in an observational study. LDLc levels were followed up.</div></div><div><h3>Results</h3><div>26 patients had an acute coronary syndrome (ACS), 11 FH; 46 % were on high-intensity statin therapy, 68 % on combination therapy statin/ezetimibe.</div><div>Mean LDLc level of the study population was 118 ± 12 mg/dl at baseline, 80 ± 18 mg/dl after 3 months, and 70 ± 15 mg/dl after 6 months (ANOVA p &lt; 0.001). The use of inclisiran was associated with significantly reduced LDLc levels of 21 % at 1 month and 44 % at 6 months.</div><div>LDLc reduction in patients with ACS was statistically significant and comparable with chronic CS. Patients receiving a background combination therapy (statin/ezetimibe) showed a greater reduction in circulating LDLc levels than patients using inclisiran alone. No significant side effects or treatment drop out were observed during follow up. Rates of subjects with LDLc levels below 70 mg/dl (Italian Drug Agency target) increased from 0 % at baseline to 56 % at 6 months (p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>In a real-world population 3–6 months of therapy with inclisiran provide consistent and effective reduction in LDLc levels without significant adverse side-effects.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 67-72"},"PeriodicalIF":2.1,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lp(a) in daily clinical routine: risk-factor for both cardiovascular events and heart-failure? A retrospective analysis of the Luebeck Lp(a) heart-failure (HF) registry in patients after myocardial infarction","authors":"Matthias Mezger ,&nbsp;Tilmann Solle ,&nbsp;Dominik Jurczyk ,&nbsp;Caroline Fatum ,&nbsp;Felicitas Lemmer ,&nbsp;Ingo Eitel ,&nbsp;Christina Paitazoglou","doi":"10.1016/j.athplu.2025.07.002","DOIUrl":"10.1016/j.athplu.2025.07.002","url":null,"abstract":"<div><h3>Background and aims</h3><div>Atherosclerotic cardiovascular disease (ASCVD) is a major health burden being the leading cause of death in Europe. Lipoprotein (a) (Lp(a)) is an important risk factor for CV events reflected by the 2019 ESC recommendation of a once in a lifetime Lp(a) measurement. Furthermore, heart-failure (HF) is the number one diagnosis for hospital admission in Germany and Europe. HF and ASCVD share common well-known risk factors, e.g. diabetes, obesity and hypertension. So far, there is scarcity of data regarding the relationship between Lp(a) and HF. We hypothesized that Lp(a) might be elevated in a high-risk ASCVD patient collective and that there might also be an association with heart-failure.</div></div><div><h3>Methods</h3><div>The Luebeck Lp(a) HF registry is a combined retrospective/prospective single-center, all-comers registry which investigates the relationship between Lp(a) and HF. The retrospective analysis reported here, comprises patients who were admitted to our heart-catheterization laboratory in the year 2021 due to ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI).</div></div><div><h3>Results</h3><div>We found that Lp(a) was assessed only in a minority of patients presenting with STEMI (33 %) and NSTEMI (14.6 %), <em>p</em> &lt; 0.001. There was no relationship between Lp(a) level and ejection fraction (EF) or NTproBNP as surrogate markers for HF, respectively. Statin pretreatment was more frequent in patients with NSTEMI (31.1 %) compared to STEMI patients (11.3 %), <em>p</em> &lt; 0.001.</div></div><div><h3>Conclusion</h3><div>Despite ESC recommendation, routine Lp(a) measurement is only rarely performed even in a high-risk patient collective. In patients with MI, we could retrospectively not observe a correlation between Lp(a) levels and heart failure, as assessed by surrogate markers as EF and NTproBNP.</div></div>","PeriodicalId":72324,"journal":{"name":"Atherosclerosis plus","volume":"61 ","pages":"Pages 29-34"},"PeriodicalIF":1.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}